U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT: July 9, 2009
APPLIED NANOSCIENCE INC.
______________________________________________________
(Exact name of registrant as specified in its charter)
Nevada 000-53090 47-0880782
____________________________ _____________________ ________________
(State or other jurisdiction (Commission file no.) (IRS employer of
Incorporation) Identification)
1902 Wright Place, Suite 200
Carlsbad, CA 92008
____________________________________________
(Address of Principal Executive Offices)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS;
APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN
OFFICERS.
On July 9, 2009, Patrick J. Gorman resigned as an officer and director of the
Company. Mr. Gorman will remain as a financial consultant to the board of
directors.
On August 3, 2009, Thomas Glenndahl was appointed Chairman of the board of
directors. Mr. Glenndahl has been a member of the board of directors since 2004.
On September 23, 2009, Staffan Lofgren was appointed to the board of directors.
Mr. Lofgren is the Managing Director of ScanAsia Consulting Ltd., a management
consulting and trading firm with offices in Hong Kong, Beijing and Shanghai. Mr.
Lofgren brings extensive international business expertise specifically in the
Asia Pacific region markets and he will assist the Company in the introduction
and marketing of the disposable NanoFense(TM) Protective Face Mask.
We do not compensate our non-employee directors for serving as a director. We
have no retirement, pension, profit sharing, stock option or insurance programs
or other similar programs for the benefit of its employees. We are accruing all
non equity direct remuneration compensation payable to Thomas K. Allen, our
President, CEO and a director. We do not have a formal plan or standard
agreement to determine the annual compensation for our officers. The decision
for all compensation is determined by the board of directors.
8.01 OTHER EVENTS.
A. Product Development:
We are the owner of a growing intellectual property platform - NEFT(TM)
(Nanoparticle - Enhanced - Filtration - Technology) combining any nanoparticle
known or engineered to be capable of destroying viruses, bacteria, fungi or
toxins with one or more hydrophobic or hydrophilic filters. The intellectual
property coverage spans the following utilization: the filter media can be
coated with nanoparticles, or have nanoparticles impregnated into an existing
filter to target specific viruses, harmful bacteria and fungi in ambient air.
The nanoparticles can be in the form of either a powder or a pellet. When
pellets are employed, the hydrophobic or hydrophilic filter is placed adjacent
to the nanoparticles. We have had patents issued in Australia, India, Mexico,
New Zealand, Russia, Singapore and Taiwan. Additionally, we continue to
prosecute foreign patent applications for our intellectual platform to achieve
maximum protection.
-2-
Our intellectual property platform also consists of trade secrets applicable in
certain cases where the disclosure of information required to obtain a patent
would divulge proprietary technology. In those cases, we may choose not to
patent parts of the proprietary technology and processes which we have developed
or may develop in the future and rely on trade secrets to protect the
proprietary technology and processes.
Our NanoFense formulation, for which a patent has been applied in the United
States, can be applied to or "coated" on most existing filter media. The
NanoFense Protective Face Mask is a disposable, single-use product incorporating
our proprietary technology.
We will be supplying the NanoFense formulation pre-mixed under our label.
We have initiated production efforts for our proprietary antimicrobial silver
nanoparticle formulation (NanoFense) which has demonstrated remarkable efficacy
against a broad spectrum of bacteria, virus, and fungi. The formulation acts as
a destructive adsorbent when applied or "coated" on existing filter media and
has been validated to deliver this performance at multiple independent BSL-3
laboratories. Testing results reflect success against the H9N2 avian influenza
simulant, Human Influenza virus A, Staphylococcus aureus including the viral
MRSA strain, Streptococcus pneumoniae, and "H"-flu.
We intend to negotiate licenses for the NanoFense technology with companies
focused in additional air filtration applications.
Our intellectual property platform (NEFT)will be marketed to both user/consumer
and industrial market segments which have a primary objective of reducing the
transmission of infectious pathogens.
B. Miscellaneous.
The Securities and Exchange Commission had made a review of our Form 10
previously filed and we have outstanding comments. It is our present intent to
respond to the comments and to bring our federal securities act filings current.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
APPLIED NANOSCIENCE INC.
Date: October 8, 2009 By: /s/ THOMAS K. ALLEN
___________________________
Thomas K. Allen
President and Director
-3-